

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**山東威高集團醫用高分子製品股份有限公司**  
**Shandong Weigao Group Medical Polymer Company Limited \***

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1066)**

**VOLUNTARY ANNOUNCEMENT  
INCREASE IN SHAREHOLDING  
BY A CONTROLLING SHAREHOLDER**

This announcement is made by Shandong Weigao Group Medical Polymer Company Limited (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) on a voluntary basis.

Reference is made to the voluntary announcement of the Company dated 14 May 2026 (the “**Announcement**”) in relation to the increase in shareholding by a controlling shareholder. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Board has been notified by its controlling shareholder, Weigao Holding, that, it has purchased an aggregate of 11,400,800 H shares of the Company in the open market, from 15 May 2026 and up to the date of this announcement, with its own funds, representing approximately 0.25% of the total issued H shares of the Company and approximately 0.25% of the total issued share capital of the Company as at the date of this announcement. From 13 May 2026 and up to the date of this announcement, Weigao Holding has purchased an aggregated of 14,953,600 H shares of the Company, for an aggregated consideration of approximately HK\$50.9 million, representing approximately 0.33% of the total issued H shares of the Company and approximately 0.33% of the total issued share capital of the Company as at the date of this announcement.

As at the date of this announcement, immediately after the increase in shareholding, Weigao Holding holds an aggregate of 2,114,709,276 H shares of the Company, representing approximately 46.76% of the total issued H shares of the Company and approximately 46.27% of the total issued shares of the Company. The aforesaid increase in shareholding fully demonstrates Weigao Holding's firm confidence in the long-term development prospects and intrinsic value of the Group, as well as its full support for the continuous and steady development of the Group.

**Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Shandong Weigao Group Medical Polymer Company Limited**  
**Long Jing**  
*Chairman*

Weihai, Shandong, the PRC, 5 June 2026

*As at the date of this announcement, the Board comprises:*

*Executive Directors*

Mr. Long Jing (*Chairman*)

Mr. Cong Rinan (*Chief Executive Officer*)

Mr. Lu Junqiang

Mr. Wang Daoming

*Non-executive Directors*

Mr. Chen Lin

Mr. Tang Zhengpeng

*Independent non-executive Directors*

Mr. Li Guohui

Mrs. Meng Hong

Mr. Li Qiang

Mr. Sun Heng

\* *For identification purpose only*